Digestery
Longevity supplements › Rapamycin and Aging › Studies

Pooled review (meta-analysis)

In mice, pooled review of 29 studies: rapamycin lowered death risk, more in females

Swindell · The journals of gerontology. Series A, Biological sciences and medical sciences · 2017

Original title: Meta-Analysis of 29 Experiments Evaluating the Effects of Rapamycin on Life Span in the Laboratory Mouse.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Rapamycin lowered death risk more in females (HR = 0.41; 95% CI: 0.35-0.48) than in males (HR = 0.63; 95% CI: 0.55-0.71). Survival rose 14.4% in hybrid mice and 8.8% in inbred strains.

The study at a glance

Type of study
Pooled review (meta-analysis)
Who or what was studied
29 studies · Laboratory mice in 29 survival studies
What was tested
Rapamycin vs control treatment, measuring survival
What it measured
The question itself: aging and age-related decline
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
The journals of gerontology. Series A, Biological sciences and medical sciences, 2017
Source
PubMed record 27519886. This page is based on the abstract only.

How much this study counts

  • ✓Pools the results of 29 studies.
  • •A pooled review is only as strong as the studies it pools.
  • ✓Measured the question itself: aging and age-related decline.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a pooled review (meta-analysis), and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer
  • Quoted in “What we found”: In 29 mouse experiments, rapamycin lowered the risk of dying, more in females (HR = 0.41) than in males (HR = 0.63); below 1 means lower risk.
  • Part of the finding “Rapamycin lengthens life in mice and other animals”.
  • Summed up in “What reviews found”: Pooled raw data from 29 mouse survival studies. Rapamycin lowered death risk, more in females (HR = 0.41) than males (HR = 0.63), and raised survival more in hybrid mice (14.4%) than inbred strains (8.8%).

Other reviews on this question

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads agreed on every checked field. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.